Skip to main content

Chai Discovery

Category: AI in Biotech / Drug Discovery

An AI-powered platform for drug discovery that predicts and designs molecular structures and interactions. Chai Discovery was founded in 2024. The company is led by Joshua Meier. Based in San Francisco, United States. Team size: 11-50. Total funding raised: $225M. Latest round: Series B. Key investors include ["General Catalyst","Oak HC/FT","Menlo Ventures","Thrive Capital","OpenAI","Dimension","Neo","Yosemite","Lachy Groom","SV Angel","Glade Brook","Emerson Collective"].

Founded
2024
Headquarters
San Francisco, United States
Team size
11-50
Total funding
$225M

Value proposition

To significantly accelerate the drug discovery process from years to months by using AI to design and validate novel therapeutics for previously untreatable diseases.

Products and solutions

["Chai-1","Chai-2"]

Unique value

Their AI models, Chai-1 and Chai-2, can perform unified predictions for a wide range of biomolecules (proteins, small molecules, DNA, RNA) and can generate and evaluate new molecular structures. They also offer a free web interface for their Chai-1 model.

Target customer

Pharmaceutical and biotechnology companies, researchers in drug discovery.

Industries served

["Pharmaceuticals","Biotechnology","Healthcare"]

Technology advantage

The core advantage is the speed and accuracy of their AI platform in predicting molecular interactions, which drastically shortens the drug development timeline. Their models are described as 'state-of-the-art' and, in some cases, outperforming existing models like AlphaFold. The ability to design novel antibodies with Chai-2 is a significant leap.

How they differentiate

Chai Discovery differentiates itself through its advanced AI models, Chai-1 and Chai-2, which have demonstrated superior performance in predicting molecular structures and designing antibodies compared to competitors. The company claims a 19% success rate in antibody design, which is a significant improvement over previous benchmarks. They are also focused on open-sourcing some of their research to accelerate scientific progress.

Main competitors

["Owkin","BenevolentAI","Formation Bio"]

Key partnerships

["OpenAI","Thrive Capital","Menlo Ventures","DST Global Partners","Eli Lilly and Company"]

Notable customers

["Eli Lilly and Company"]

Major milestones

["Secured $70M in Series A funding.","Developed and released Chai-1, an AI model for predicting molecular structures that outperforms Google DeepMind's AlphaFold on certain tasks.","Launched Chai-2, an AI model for antibody design with a reported 19% success rate.","Raised $130M Series B at $1.3B valuation, becoming an AI unicorn.","Announced strategic collaboration with Eli Lilly and Company to accelerate biologics discovery."]

Growth metrics

Specific growth metrics are not publicly available.

Market positioning

Chai Discovery is positioned as a cutting-edge AI-driven biotechnology company with a focus on developing foundational models for drug discovery. The company has gained significant attention for its technological advancements and strong backing from prominent investors, positioning it as a key innovator in the field.

Geographic focus

United States

Patents and IP

Information on specific patents is not publicly available at this time.

About Joshua Meier

Co-Founder at Chai Discovery, previously Senior Director of AI Research at Absci, Research Scientist at Meta, and Researcher at OpenAI.

Official website: